Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H773
UPID:
DCTP1_HUMAN
Alternative names:
Deoxycytidine-triphosphatase 1; RS21C6; XTP3-transactivated gene A protein
Alternative UPACC:
Q9H773
Background:
dCTP pyrophosphatase 1, also known as Deoxycytidine-triphosphatase 1, plays a crucial role in nucleotide metabolism by hydrolyzing deoxynucleoside triphosphates (dNTPs) to their monophosphates. It exhibits a strong preference for dCTP and its analogs, including 5-iodo-dCTP and 5-methyl-dCTP, showcasing higher efficiency towards these substrates. This specificity suggests a protective mechanism against the incorporation of genotoxic nucleotide analogs into DNA or RNA.
Therapeutic significance:
Understanding the role of dCTP pyrophosphatase 1 could open doors to potential therapeutic strategies. Its ability to prevent the incorporation of harmful nucleotide analogs into genetic material positions it as a key player in safeguarding genome integrity.